Skip to main content

Table 1 Recent clinical trials concerning immune-checkpoint inhibitors in pancreatic cancer

From: Tumor microenvironment participates in metastasis of pancreatic cancer

NCT Number Status Phase Tumor types Interventions Monotherapy/Combination
NCT02305186 Recruiting Phase 1/2 Pancreatic Cancer Pembrolizumab + Neoadjuvant chemoradiation Combination
NCT02930902 Recruiting Phase 1 Pancreatic Cancer Pembrolizumab + Paricalcitol + Surgical Resection or Pembrolizumab + Paricalcitol + Surgical Resection + Gemcitabine + Nab-pacilitaxel Combination
NCT02451982 Recruiting Phase 1/2 Pancreatic Cancer Cyclophosphamide + GVAX pancreatic cancer or Cyclophosphamide + GVAX pancreatic cancer + Nivolumab Combination
NCT02866383 Recruiting Phase 2 Metastatic Pancreatic Cancer Nivolumab + Ipilimumab + Radiotherapy Combination
NCT03519308 Recruiting Early Phase 1 Pancreatic Cancer Nivolumab + Nab-Paclitaxel + Gemcitabine + Paricalcitol Combination
NCT03404960 Recruiting Phase 1/2 Pancreatic Cancer Niraparib + Nivolumab or Niraparib + Ipilimumab Combination
NCT03104439 Recruiting Phase 2 Microsatellite Stable Colorectal Cancer
Pancreatic Cancer
MSI High Colorectal Cancer
Nivolumab + Ipilimumab + Radiation therapy Combination
NCT01473940 Active, not recruiting Phase 1 Ductal Cell Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer
Ipilimuma + Gemcitabine hydrochloride Combination
NCT01896869 Suspended Phase 2 Metastatic Pancreatic Adenocarcinoma Ipilimumab + Vaccine + FOLFIRINOX Combination